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INTRODUCTION 
Human immunodeficiency virus (HIV) infection/Acquired 
Immunodeficiency Syndrome is a global  pandemic, with cases reported 
from virtually every country. With more than 35 million fatalities, the AIDS 
epidemic now  ranks  alongside the  influenza  pandemic of the early 1900s 
and the Bubonic plague of the fourteenth century in terms of fatalities.
[1]
 
Statistics for the end of  2008  indicate that around 33 million people 
are living with HIV, the virus that causes AIDS. Each year around 2.7 
million more people become infected with HIV and 2 million die of 
AIDS.
[2]
Although HIV and AIDS are found in all parts of the world, the 
worst  affected  region is sub-Saharan Africa, where in a few countries more 
than one in five adults are infected with HIV. The epidemic is spreading 
most rapidly in Eastern Europe and Central Asia, where the number of 
people living with HIV increased to 67% between 2001 and 2008. 
Gastroenterological manifestations are quite common in advanced 
HIV infection/ AIDS and are sometimes the initial manifestations or AIDS 
defining illness. Liver involvement is unique since it can be because of direct 
involvement, opportunistic infections (OI) with co-infection of one or more 
hepatotoxic viruses, or because of toxicity due to antiretroviral drugs.
[3]
 
 
  
2 
 
HEPATOBILIARY MANIFESTAIONS OF HIV/AIDS: 
Liver disease has assumed a far greater importance as a cause of 
morbidity and  mortality in patients infected with human immunodeficiency 
virus (HIV) because of their increased life expectancy as a result of 
antiretroviral therapy  (ART). Presence of liver disease is a frequent finding 
in AIDS. Hepatomegaly may be detected on examination in most patients. 
Hepatomegaly is usually associated with one or more biochemical test 
abnormalities, although significant jaundice due to parenchymal disease is 
uncommon.  
As with other organ systems, the spectrum of hepatic infections in 
patients with HIV evolves as immunocompromise advances. Hepatobiliary 
disease in HIV-infected patients can be divided into two groups: Those with 
severe immunosuppression, who commonly have opportunistic infections, 
and those with suppressed HIV viral loads and minimal immunosuppression. 
Clinical manifestations of hepatobiliary disease can vary from no symptoms 
to liver failure.      
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Table 1.1 - MAJOR CAUSES OF LIVER INJURY IN HIV-INFECTED PATIENTS 
DRUGS 
ART: NRTI, NNRTI, PI 
Antimicrobial agents: 
Antituberculosis (INH, rifampin) 
Macrolides (clarithromycin, azithromycin) 
Antifungal (ketoconazole, itraconazole, fluconazole) 
Antipneumocystis (TMP-SMX, pentamidine, dapsone) 
INFECTIONS 
Viral (HAV, HBV, HCV, HDV, GBV-C, CMV, HSV, VZV, EBV) 
Mycobacterial (Mycobacterium avium, Mycobacterium tuberculosis, other 
Mycobacteria) 
Fungal (cryptococcus, histoplasma,  coccidioides, candida) 
Protozoan (pneumocystis, toxoplasma, microsporidia, cryptosporidium) 
BILIARY TRACT INFECTIONS 
HIV cholangiopathy, Acalculous cholecystitis 
NEOPLASMS AND VASCULAR LESIONS 
Kaposi sarcoma, Lymphoma, Peliosis hepatitis 
STEATOSIS WITH LIPODYSTROPHY 
HCV/HIV coinfection Drug-associated  (PI and NRTI). 
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DRUGS: 
Drug-induced liver injury has emerged as the most prevalent cause of 
liver test abnormalities and is related to the increasing array of antiretroviral 
medications. Use of prescription or non-prescription drugs as well as herbal 
remedies should also be considered a cause of abnormal liver test results in 
the HIV-infected patient. Before HAART, drug hepatotoxicity was most 
commonly due to sulfonamides, and the increased frequency of adverse 
reactions to these medications is well recognized in AIDS. 
The lactic acidosis syndrome, characterized by marked hepatomegaly, 
steatosis, metabolic lactic acidosis, and liver failure, is now well recognized. 
The liver tests typically show a hepatocellular pattern but can be normal or 
minimally increased. Hepatic steatosis is evident on imaging of the liver. 
Although reversal has occurred in some patients following drug withdrawal, 
most patients have worsening disease and death. Liver transplantation is 
curative. 
The incidence of drug induced hepatotoxicity, its mechanisms, 
evaluation, management, analyses of various studies on the risk factors and 
prognosis are described in detail in Literature review. 
INFECTIONS: 
Viral Infections, of the liver are often because of herpes viridae 
family. CMV is detected frequently in autopsies of severely 
immunosuppressed patients with CD4 counts less than 100/mm
3
 and is often 
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a component of systemic involvement .CMV infects every type of cell within 
the liver. CMV infection is being detected earlier now owing to pp65 antigen 
flow cytometry and CMV polymerase chain reaction.  
Hepatitis secondary to HSV occurs in patients with extensive herpetic 
ulcers elsewhere. Pathologically, HSV hepatitis is characterized by 
multinucleated  hepatocytes and Cowdry type A intranuclear inclusion 
bodies that may be differentiated from those of CMV by specific immuno-
histochemistry. Varicella-zoster virus, EBV, and adenovirus are the other 
agents responsible for viral hepatitis in patients with HIV. 
Clinical manifestations and  histologic features of  viral hepatitis from 
HBV, HCV, or hepatitis D virus are altered in the presence of HIV 
coinfection but in remarkably different ways for each virus. Because of 
common epidemiologic risks of transmission including sexual and  
parenteral exposures, coinfection of hepatitis B virus (HBV) with HIV is 
common. Decreased response to HIV-ART and a higher risk of hepatic 
decompensation was observed in HBV/HIV-coinfected patients compared 
with those of HIV monoinfected patients.
 [4]
 Clinical and autopsy studies in 
AIDS patients have reported up to a 90% sera prevalence of hepatitis B 
markers indicating past or present infection. 
Concurrent HIV and HBV infections lead to alterations of HBV 
antigen-antibody display, viral replication, and clinical consequences. 
Several reports have described reappearance of hepatitis B surface antigen 
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(Bag) in HIV-infected patients previously thought to be immune to hepatitis 
B virus as indicated by the presence of anti-HBs.
[4]
Recurrence of Bag may 
arise from either reinfection or reactivation with advanced 
immunodeficiency. In addition, there is an accelerated loss of naturally 
acquired anti-HBs even in those patients who remain HBsAg negative. With 
loss or reduction in immunity to HBV, there is an increased prevalence of 
hepatitis B e antigen expression, elevated  mean levels of DNA polymerase, 
and increased titers of anti–hepatitis B core antigen.
[5]
 
Acquisition of the chronic carrier state is also much more likely in the 
HIV-infected  patient, especially if infection occurs when immunodeficiency 
is more advanced. Thus, a larger proportion of patients with HIV and 
hepatitis B infections have a chronic carrier state, with highly infectious 
serum and body fluids, compared with those who are HIV negative. 
Although HIV infection leads to more prevalent chronic HBV carriage, it 
appears to attenuate the severity of biochemical and histologic liver disease 
in most, but not all patients.  
In one study, the mean alanine aminotransferase (ALT) level 
correlated with CD4 lymphocyte count. The mechanism for reduced  
hepatitis B virus–related liver injury following HIV infection is not certain 
but has been attributed to a diminution in lymphocyte-mediated 
hepatocellular injury as a result of HIV effects on lymphocytes. In those 
patients without  serologic evidence of  past or present hepatitis B virus and 
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HIV infection, vaccination  appears to be  ineffective, regardless of  the  
stage of immuno compromise. Sometimes the institution of HAART in a 
chronic carrier of hepatitis B virus can have catastrophic consequences. 
Patients may develop an acute flare of hepatitis that can be severe leading to 
fulminant  hepatic failure. However, the proportion of coinfected patients 
who develop an acute hepatitis B flare following use of HAART is 
unknown. It is believed that reconstitution of immune function with HAART 
leads to production of antibody that is directed to infected  hepatocytes as in 
the normal host. Inclusion of  lamivudine, which has potent antiviral effects 
on hepatitis B virus, in the HAART regimen may reduce the likelihood of 
acute hepatitis B.
[5]
The consequences of HIV infection on delta hepatitis 
appear similar to those of HBV, although far fewer patients have been 
studied. 
The prevalence of HCV in those with HIV infection depends on the 
risk group evaluated  and the assay used. Prevalence is highest in injection 
drug users (52% to 89%)
[6] 
and hemophiliac patients with HIV, whereas in 
military populations and non–drug users, the prevalence is much lower, 
ranging from 1% to 11%. Assaying antibodies to hepatitis C virus alone, 
rather than hepatitis C virus RNA, may underestimate the true prevalence, 
because loss of antibody may occur with progression of 
immunodeficiency.
[4],[5]
Unlike hepatitis B virus, the clinical course of 
hepatitis C virus appears to worsen as HIV-related immune compromise 
8 
 
advances. This has been best documented in HIV infected hemophiliac 
patients. Studies in large cohorts of  hemophiliac patients have demonstrated 
dramatic increases in hepatitis C virus RNA levels with progressive HIV 
disease, associated with aspartate aminotransferase (AST) elevations and 
hepatomegaly. Coinfected patients also have a higher rate of active cirrhosis 
on biopsy and an accelerated course to clinical cirrhosis and liver failure.  
Factors that predict fibrosis and progression to cirrhosis in coinfected 
patients include: older age at infection, higher alanine aminotransferase 
levels, higher inflammatory activity, alcohol consumption of more than 50 
g/day and CD4+ T cell count of less than 500 cells/mm.
[3],[7],[8]
The  
mechanism for this more rapid disease course is unknown but has been 
similarly recognized in other immunocompromised patients. Because 
patients with late-stage HIV often have multiple life- threatening infections, 
HCV alone is not an independent determinant of mortality. 
However, as HIV-infected patients are living longer owing to 
HAART, hepatitis C virus–induced liver disease and its consequences (e.g., 
hepatocellular cancer) are assuming more clinical relevance. Like hepatitis 
B, hepatitis C virus does not cause progression of HIV disease.
[6]
The effect 
of HAART on hepatitis C viral dynamics and liver injury is variable. Some 
studies have found attenuation of disease, whereas others had documented 
exacerbations reflected by increases in serum transaminases. Hepatitis C 
viral load has also been variably affected.
[9]
The role of interferon therapy for 
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HIV/HCV coinfected patients remains unsettled. α-Interferon is less 
effective for treating hepatitis C virus liver disease in coinfected patients. 
More recently, combination therapy of Peg-interferon and ribavirin has 
shown promise.
[10]
 
Mycobacterial Infections, most common opportunistic pathogen 
affecting the liver. Infection with MAC manifests with systemic symptoms 
and signs, such as fever, abdominal pain, wasting, and biliary obstruction 
secondary to enlarged  lymph nodes at the porta hepatis. It is ordinarily seen 
in late stage AIDS patients with CD4 count less than 50 cells/mm
3
. MAC is 
detected in 20% to 55% of autopsies and  in 10% to 30% of liver biopsies in 
patients with AIDS. Blood cultures are the most sensitive test for diagnosis 
of MAC. On the other hand, liver biopsy showing diffuse, poorly formed 
noncaseating granulomas is necessary for definitive diagnosis of liver 
involvement. Liver tissue culture is needed to distinguish between different 
Mycobacterium species. Liver biopsy has been reported to be more sensitive 
than bone marrow biopsy in diagnosing disseminated mycobacterial 
infection in AIDS.
[11]
Extrapulmonary Mycobacterium tuberculosis (MTB) 
infection involving the liver occurs in 5% to 10% of HIV-related 
tuberculosis cases and  may present with tuberculous liver abscess in 
severely immune compromised patients.
[12]
As the virulence of MTB is 
greater  than in the other species of Mycobacterium, it may infect the 
patients who have higher CD4 counts, more than 200/mm
3
.
[13]
The specific 
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diagnosis is made by culture and polymerase chain reaction of blood, urine 
or tissue specimen including  liver. Acid-fast bacilli may be seen in the liver 
histology, which is typically characterized by presence of caseating 
granulomas. Rarely, liver infections with other mycobacterial species such as 
Mycobacterium kansasii, Mycobacterium xenopi, and Mycobacterium 
genavense have also been reported.  
Fungal Infections  infecting  the liver are Cryptococcus neoformans, 
Histoplasma capsulatum, Coccidioides immitis and Candida albicans. They 
are uncommon and ordinarily seen in the setting of disseminated disease,  in 
patients with less than 100 CD4 cells/mm
3
. Liver histology often reveals 
poorly formed granulomas with minimal inflammatory reaction. 
 Meningitis is the most common manifestation of cryptococcal disease 
in HIV-infected patients. Liver involvement occurs because of 
haematogenous spread. The common presenting features are fever and 
hepatosplenomegaly. Progressive disseminated histoplasmosisis often the 
first sign of immunodeficiency in patients with AIDS in endemic areas.
[14]
 
Constitutional symptoms along with hepatosplenomegaly and 
lymphadenopathy are the common features.  
C. immitis infection presents with pulmonary involvement, hepatic 
infection is again secondary to disseminated disease. Systemic infection and 
liver involvement with candidiasis are quite rare unless the patients are 
neutropenic. The symptoms are nonspecific such as nausea, vomiting, 
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abdominal pain, and hepatomegaly. C. neoformans and H. capsulatum may 
be rapidly detected by polysaccharide capsular antigenemia; There are also 
rare reports of Aspergillus fumigatus causing liver  abscess and disseminated 
Sporothrix schenckii involving the liver. . 
Protozoa, are rare pathogens causing infections in patients with AIDS. 
The routine prophylaxis with trimethoprim/sulfamethoxazole (TMP-SMX) 
has reduced the incidence of Pneumocystis jirovecii, Toxoplasma gondii, 
and Listeria monocytogenes. In the past P. jirovecii (formerly Pneumocystis 
carinii) hepatitis was associated with the prophylactic use of aerosolized 
pentamidine for pneumocystis pneumonia.
[15],[16]
 Inhalation  failed to provide 
adequate drug levels to extra pulmonary sites and up to 39% of such patients 
developed  extrapulmonary spread.
[17]
 Abdominal CT scan may demonstrate 
diffuse and punctate calcifications in the liver. Liver biopsy shows foamy 
nodules that are periportal or diffuse containing numerous Pneumocystis 
cysts that stain with Gomori's methenamine-silver. 
T.gondii also involves the liver rarely through haematogenous 
dissemination and may present with granulomatous disease or hepatitis. 
Diagnosis is made by culture or microscopic examination of  Giemsa-stained 
specimens. Microsporidial infection of the liver is rare. Light microscopy 
reveals focal granulomatous and suppurative necrosis, mainly in the portal 
area, accompanied by characteristic spores. 
Strongyloides stercoralis, a helminth of the nematode family, may result in a 
hyperinfection syndrome in the immuno compromised patient. The liver is 
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involved through the haematogenous spread of the larvae from the 
gastrointestinal tract. Entamoeba histolytica may invade the bowel wall and 
spread to the liver, forming an abscess. Reactivated Leishmania donovani is 
another rare infection of the liver .The biliary tree including the gall bladder, 
is a common site of infection in HIV infected patients with 
immunosuppression. It may be involved in the form of acalculous 
cholecystitis or cholangiopathy. 
Hepatic microabscesses or macroabscesses are most likely to occur if 
the patient is neutropenic, especially following chemotherapy for non-
Hodgkin's lymphoma. Kaposi's sarcoma, which is caused by infection with 
human herpesvirus 8 (HHV-8) has a predilection for periportal regions of the 
liver and is seen in 10% to 15% of liver biopsies. Tumor nodules appear 
grossly as violaceous or hemorrhagic masses within hepatic parenchyma. 
Microscopically, the characteristic spindle cells and vascular slits of Kaposi's 
sarcoma usually directly abut normal-appearing liver tissue. Hepatic 
involvement by non-Hodgkin's lymphoma may be the index manifestation of 
AIDS in homosexual men and may be the primary site of the neoplasm. The 
lesions are usually focal and  may be large. In addition, Hodgkin's disease in 
the AIDS patient tends to be more aggressive histologically and clinically, 
spreading rapidly to extranodal sites making liver involvement more likely. 
Bacillary peliosis hepatitis may be caused by either Bartonella henselae or 
Bartonella quintana. 
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Biliary tract involvement in AIDS may result in marked liver test 
abnormalities and  right upper quadrant symptoms, jaundice is unusual. A 
syndrome resembling sclerosing cholangitis with papillary stenosis is well 
recognized and has been termed AIDS cholangiopathy. Patients 
characteristically develop significant upper abdominal pain in association 
with marked elevation of alkaline phosphatase, and minimal elevations of 
bilirubin, AST, and ALT. 
Other less common causes of biliary tract disease in AIDS include 
primary bile duct lymphoma, epithelial angiomatosis, lymphomatous nodal 
obstruction, Kaposi's sarcoma, and biloma. In addition, chronic pancreatitis 
or choledocholithiasis may lead to biliary obstruction, although their 
incidence is not clearly increased in HIV infection.
[3][4]
 
EVALUATION: 
The initial decision in evaluating the AIDS patient with jaundice, 
hepatomegaly, or both, is to determine whether the findings are due to 
intrahepatic or extrahepatic disease. Simultaneous disease in both sites must 
also be considered. A history of mild jaundice, often in association with 
fever and constitutional symptoms, is more consistent with intrahepatic 
disease, whereas symptoms of deep jaundice associated with pain of 
relatively acute onset suggest extrahepatic disease.  
Careful review of medications, both  prescription and non-
prescription, is essential. Because the clinical history and the finding of 
symptomatic hepatomegaly are nonspecific, further evaluation is always 
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necessary. Elevations of ALT or AST or both are common, but neither the 
pattern nor the extent of elevation of these tests appears to correlate with 
specific findings in the liver. Significant elevation of the transaminases 
favours a drug-induced or viral cause. In contrast, marked elevation of 
alkaline phosphatase correlates statistically with the presence of MAC 
infection in the liver in AIDS when extrahepatic obstruction is absent.  
The indications for liver biopsy for the patient in whom intrahepatic 
disease is suspected are not well defined. Biopsy is appropriate when 
symptomatic, treatable disease of the liver is suspected and when a specific 
diagnosis of hepatic disease is needed. An extrahepatic cause for jaundice is 
suggested on CT or ultrasonography by the presence of dilated ducts or other 
biliary and/or pancreatic abnormalities. Once extrahepatic obstruction is 
recognized, the possibility of papillary stenosis associated with AIDS 
cholangiopathy must be considered as well as the possibility of 
choledocholithiasis or other disorders, depending on the imaging studies. 
Further evaluation, when indicated, may include endoscopic retrograde 
cholangiopancreatography (ERCP) if CT or ultrasonography demonstrates 
extrahepatic biliary ductal dilatation. Ampullary and duodenal biopsy 
specimens or bile and/or biliary cytology (with appropriate staining) 
collected during ERCP can be examined for the presence of viruses, 
protozoa, or neoplastic cells. 
[2],[3],[4]
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REVIEW OF LITERATURE 
The advent of highly active antiretroviral therapy (HAART) has 
dramatically reduced the clinical impact of infection with HIV1,2.The 
terminology “highly active antiretroviral therapy”(HAART) refers to use of 
combinations of three antiretroviral agents for treatment of HIV infection. 
To date, most clinical experience with use of HAART in treatment-naïve 
individuals has been  based on three types of combination regimens: NNRTI 
based (1 NNRTI + 2 NRTI), PI-based (1-2 PI + 2 NRTI), and triple NRTI-
based regimens. Most experience in India is with NNRTI based regimens. 
HAART INDUCED LIVER DISEASE: 
             Highly active antiretroviral therapy (HAART) has dramatically 
changed the course of HIV infection, having decreased the morbidity and 
mortality derived from  classical opportunistic infections. In the recent era of 
ART therapy (between 2000 and 2005), the estimated expected survival for a 
25-year-old HIV-infected person was 39 years, compared  with only 7 years 
for     the same individual in the pre-ART era.
[18]
 
Antiretroviral drug-related  liver injury (ARLI) is a common cause of 
morbidity, mortality and treatment discontinuation in HIV-infected 
patients.
[19] 
Prevention and management of ARLI have emerged as major 
issues among HIV-infected patients in the era of HAART.
[20]
Virtually every 
licensed antiretroviral medication has been associated with liver enzyme 
elevations, although certain drugs may cause liver injury more frequently 
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than others. Discerning  the  role of HAART  in hepatotoxic reactions of 
HIV patients may be difficult due to frequent preexisting liver  pathology, 
such as that arising from infection with hepatitis B or C virus. Moreover, 
poly pharmacy is common in HIV-infected individuals, and a very large 
number of medications are known to have effects on liver function and drug 
metabolism. 
In addition, certain comorbidities, such as chronic hepatitis B (HBV) 
or hepatitis C (HCV) infection, may predispose  patients to ARLI.
[21]
 Several 
major mechanisms of ARLI have been described, including metabolic host-
mediated injury, hypersensitivity reactions, mitochondrial toxicity, and 
immune reconstitution  phenomenon. The management of ARLI should be 
based on its clinical severity and underlying pathogenic mechanism. 
Therefore, it is imperative to rule out other potential aetiologies before 
discontinuing HAART drugs. 
CLINICAL IMPACT: 
With the widespread use of HAART and the availability of new 
antiretroviral medications, ARLI has gained prominent attention owing to its 
negative impact on clinical outcomes. Drug-associated hepatotoxicity also 
creates an economic burden on already strained medical budgets, since 
additional visits and hospital admissions are often required for appropriate 
patient care and management.
[19]
 Furthermore, antiretroviral drug 
discontinuation hampers maintenance of HIV suppression. 
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The severity of ARLI may range from the absence of symptoms to liver 
decompensation, and the outcome can range from  spontaneous  resolution to 
liver failure and death.
[22],[23]
 In one study, severe  hepatotoxicity with acute 
hepatic necrosis was recognized in 2% of HIV-infected patients dying from 
liver disease. Furthermore, in a large ACTG cohort of nearly 3000 patients 
initiating HAART, the most common grade 4 adverse events were liver 
related; this risk was increased in patients with underlying chronic viral 
hepatitis.
[24]
 
Fortunately, the vast majority of episodes of ARLI are asymptomatic, 
and most ALT elevations resolve spontaneously, as described for many other 
medications, probably through a process called 'adaptation'.
[25]
 However, in a 
minority drug-induced liver injury can be overt and have serious 
consequences. Therefore, it is critically important for the clinician to 
understand  risk factors  associated  with  poor outcomes  and  the 
pathogenic mechanisms of disease. 
In a recent American study, which evaluated the causes of death of 
HIV-infected individuals, discontinuation of ART due to hepatotoxicity 
increased from 6% in 1996 to 31.8% in 1998-1999 among those mortalities . 
More recently, Kramer and colleagues have highlighted the increase in the 
number of cases of fulminant liver failure in HIV/HCV-coinfected 
individuals during the HAART era, even after excluding patients with 
advanced liver disease and adjusting by alcohol intake. 
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Drug  liver toxicity has impacted on the recommendations for antiretroviral 
therapy in certain scenarios. Thus, the use of nevirapine (NVP) has been 
recommended to be avoided as part of post-exposure prophylaxis regimens. 
The reason for that was the occurrence of fulminant hepatitis in two cases 
and severe liver toxicity in 12 other healthy subjects who received a NVP-
including HAART regimen after HIV exposure. 
However, NVP seems to be safe when administered to mother and 
child as a single dose for prevention of mother-to-child HIV 
transmission.
[3],[4]
 
DEFINITION OF LIVER INJURY: 
ARLI is defined by elevations  in  liver enzymes in serum, with 
alanine aminotransferase (ALT) characteristically greater than aspartate 
aminotransferase (AST). To date, there has been broad variability in the 
criteria used in clinical studies to categorize the severity of hepatotoxicity. 
Some studies have utilized ALT parameters as minimal as two times the 
upper limits of normal.
[26]
while others have employed  an  absolute  
threshold (e.g., >100 IU/ml), regardless of baseline liver function tests.
[27] 
The clinical relevance of these elevations is uncertain. 
More recently, the AIDS Clinical Trials Group (ACTG)  has defined a 
grading scheme against the patient's baseline serum aminotransferase 
concentrations. For example, in patients with a normal prêtherapy ALT or 
AST, hepatic injury is graded as moderate or severe based on a 5-fold or 10-
19 
 
fold increase in aminotransferases, respectively.
[28]
In patients with abnormal 
liver enzymes prior to therapy, a >3.5-fold or a 5-fold increase in ALT or 
AST is considered indicative of moderate or severe hepatotoxicity, 
respectively.
[29]
 
DEFINITIONS OF HAART-ASSOCIATED HEPATOTOXICITY:  
The AIDS Clinical Trials Group currently uses the following toxicity 
grading scale: 
PATIENTS WITH NORMAL PRETREATMENT ALT/AST: 
Grade 0 hepatotoxicity  <1.25 times the ULN (upper limit of normal) 
Grade 1 hepatotoxicity   1.25 to 2.5 times the ULN 
Grade 2 hepatotoxicity   2.5 to 5 times the ULN 
Grade 3 hepatotoxicity   5.1 to 10 times the ULN 
Grade 4 hepatotoxicity   >10 times the ULN 
There is a  grading scale for the HAART-associated cholestasis: 
Grade 0 cholestasis    <1.1 times the ULN 
Grade 1 cholestasis    1.1 to 1.5 times the ULN 
Grade 2 cholestasis    1.6 to 2.9 times the ULN 
Grade 3 cholestasis    3 to 5 times the ULN 
Grade 4 cholestasis   >5 times the ULN 
For patients with elevated pre-treatment ALT/AST, changes are 
compared to baseline rather than upper limit of normal. Grades 0 and 1 are 
identical, but grade 2 is  associated with ALT/AST 2.6 to 3.5  times baseline, 
 grade 3 is 3.6 to 5 t
baseline.
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On the other hand, drug-induced liver injury that  is associated with an 
elevated direct bilirubin and clinical jaundice portends a poor clinical 
outcome. A cholestatic profile should only be considered when there is an 
associated increase in serum alkaline phosphatase as well as bilirubin. 
Elevated  aminotransferases  also need to be interpreted within their clinical 
context. For example, increased liver enzymes in a patient with chronic HBV 
infection do not necessarily imply drug injury but may reflect HBV-related 
hepatic flares, which often occur during the natural course of the disease. 
INCIDENCE AND RISK FACTORS: 
After initiating HAART, the reported  incidence of severe liver 
toxicity ranges from 2 to 18 %.
[21],[27],[29],[34-42]
Differences in study outcomes 
may reflect  heterogeneity in patient  populations, frequency of liver 
enzymes determinations, other exogenous exposures (e.g., alcohol), 
medication  prescribing  patterns, prevalence of chronic viral hepatitis, and 
criteria used for defining severe hepatotoxicity. 
Hepatitis B and C co-infections: 
Liver toxicity, especially severe toxicity (grades 3 and 4),is clearly 
more frequent in HCV and/or HBV co-infected individuals treated with 
HAART.
[33],[22-25],[34-38]
In one study, a higher  risk of hepatotoxicity was 
found in patients carrying HCV genotype 3 (HCV-3) compared to other 
genotypes.
[40]
 The clinical implications of this finding are 2-fold. On one 
hand, the presence of HCV-3 may impact on the selection of HAART 
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regimen, choosing  those  with  less  potential for hepatotoxicity. On the 
other hand, since genotype 3 shows a higher response to α-interferon 
(IFN)and  ribavirin (RBV), anti-HCV treatment should be given if no major 
contraindication is present. 
In addition  to drug  injury, flares in serum transaminase 
concentrations in a patient with chronic HBV can be related to several 
different factors, including viral  rebound  after withdrawal  of  effective 
anti-HBV therapy, break through of drug-resistant HBV strains or 
spontaneous flares of HBV viraemia.
[41],[43-45]
The clinician must bear this in 
mind before misinterpreting hepatic flares as drug injury. 
Alcohol: 
Alcohol is a known heaptotoxin and its use has been associated with 
an increased risk of ARLI in the studies that have examined this 
variable.
[21]
Chronic use may also predispose to hepatocyte injury by 
increasing  oxidative damage to mitochondrial DNA and depleting stores of 
glutathione, an important scavenger of free oxygen radicals.
[46]
 
Other Predisposing Factors: 
Multiple studies have demonstrated that the risk of liver injury is 
increased in those with aminotransferase elevations prior to initiating 
HAART.
[35],[37-40] 
Other  risk factors associated with ARLI include older age 
[7]
,female gender
[40],[47]
,first exposure to antiretroviral treatment
[41]
 and 
significant CD4 cell gains following HAART initiation.
[29,48] 
More recently, 
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an association  between  the presence of advanced stages of liver fibrosis and 
greater risk of ARLI has been reported.
[49]
The mechanism for this 
observation is unclear, but it could be the consequence of compromised 
hepatic clearance with subsequent drug overexposure in patients with 
cirrhosis.
[84]
 
ANTIRETROVIRALS: 
Studies that have evaluated the risk of liver injury associated with a 
particular antiretroviral  agent or class are often conflicting. The effect of a 
specific drug is difficult to ascertain because of the widespread use of 
combination therapy. 
Nucleoside Reverse Transcriptase Inhibitors: 
   NRTIs are associated with low incidence of elevated liver enzyme 
values, 5% to 6%
[29],[51],[52]
 ranging from 7% with zidovudine, 9-13% with 
stavudine and 16% with didanosine.
[53]
Newer NRTI such as emtricitabine, 
abacavir and tenofovir are associated with a low incidence of mild 
asymptomatic aminotransferase elevations.
[54]
 
Mitochondrial toxicity is an infrequent but distinctive type of 
hepatotoxicity  associated with the use of NRTI that may evolve to acute 
liver failure with severe hepatomegaly and lactic acidosis.
[55]
This 
complication generally occurs after several weeks or months of NRTI 
treatment. However, nucleoside analogues differ widely in their propensity 
to induce mitochondrial toxicity. Potency estimations in vitro gave a 
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descending  hierarchy of their potency: zalcitabine, didanosine, stavudine, 
zidovudine and, finally, abacavir, as least toxic.
[54]
In-vitro data support 
additive or  synergistic mitochondrial toxicity of some NRTI combinations 
[56]
such as stavudine and didanosine.
[56-58]
 
Two clinical entities of hyperlactatemia are associated with 
mitochondrial toxicity. The time to presentation of NRTI-related 
hyperlactatemia is reported to be 3 to 20 months, with a median time of 9 
months. Many patients have a 2- to 4-week prodrome, the most common 
symptoms are nausea, vomiting, vague abdominal pain, and abdominal 
distension, the prognosis is usually good as long, as the use of NRTIs is 
stopped, but long-term sequelae may occur. The second associated 
mitochondrial  injury is the lactic acidosis syndrome, reported to occur 1 to 4 
Cases/1000 patient-years. This condition is much more ominous and is 
associated  with  multiorgan failure and a mortality rate of 30% to 100% 
even if ART is stopped.
[59]
 
Hypersensitivity reactions have been linked to abacavir and are 
characteristically seen in patients with HLA-B*5701 background.
[60]
Re 
exposure to abacavir can be fatal.Incidents of unexplained liver disease in 
HIV-infected individuals have recently been reported in which clinical 
manifestations of portal hypertension are often predominant. Didanosine 
exposure seems to be involved in almost all and nodular regenerative 
hyperplasia is a frequent histological finding.
[61,62] 
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Nonnucleoside Reverse Transcriptase Inhibitors: 
The incidence of elevated liver enzyme values with either drug has 
been  reported to range from less than 2% to 20%.
[63],[64] 
However, severe 
liver toxicity, occurring with early latency, has been reported in HIV-
infected and HIV-seronegative individuals. Warnings against the use of 
nevirapine  for  post exposure prophylaxis were issued after some 
individuals developed  hepatic failure requiring  liver 
transplantation.
[65]
Concomitant use of  NNRTIs and PIs also seems to 
increase the risk of elevated liver enzyme values.
[66],[67],[68]
Women  who have 
CD4 counts  higher  than 250 cells/mL are especially at risk for nevirapine-
related  fulminant  hepatic failure.
[69]
Several  studies continue to find  
women at greater  risk  than men for elevated  liver enzyme values, 
especially with nevirapine, this finding remains unexplained.
[70],[71]
 
Nevirapine seems to be associated with two types of toxicities. An 
initial  hypersensitivity  reaction  characterized by rash, fever, and elevated 
liver enzyme values occurring in the first 4 to 6 weeks is thought to represent 
an  idiosyncratic reaction of the host and is not related to the dose of the 
drug. For reasons that are unclear, women who have CD4 counts of 250 
Cells/ml and  higher and men who have CD4 counts of 400 cells/ml or 
higher Seem to be at increased risk of this type of toxicity.
[72]
                       
Furthermore, a low body mass index is another independent risk factor for 
nevirapine hypersensitivity reaction.
[70]
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In addition, nevirapine has been associated with a late risk of toxicity 
occurring at 6 to 12 months.
[73-75]
This type of toxicity  seems to increase in 
incidence over time, probably results from a direct effect of the drug, and is 
thought not to represent an immune- mediated process. Persons with an 
HLA-DRB1*0101 background  have an  increased propensity for developing 
nevirapine-associated hypersensitivity.
[76-78] 
 
Idiosyncratic Drug-related Toxicity: 
  In other studies, a different pattern of drug injury with nevirapine use 
has emerged, with onset of liver enzyme elevations occurring beyond 16 
weeks of therapy, consistent with direct or  idiosyncratic host-mediated liver 
injury.
[47],[48]
This late onset of  hepatotoxicity with  NNRTI  is  more 
common in patients with underlying chronic viral HBV and/or HBV&HCV 
infection, as has been described with many other antiretroviral agents. In 
patient populations that vary in terms of chronic viral hepatitis prevalence, 
NNRTI-associated liver injury can vary from 15%
[48]
 to as low as 
3%.
[79]
Specific genetic  polymorphisms of  metabolizing enzymes and drug 
transporters may also increase the risk of  this complication.
[80,81]
 It should be 
highlighted  that hepatotoxicity  with either  nevirapine or efavirenz does not 
appear to increase the risk of developing liver injury on exposure to the 
alternative  NNRTI.
[82],[83] 
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Protease Inhibitors: 
The  phenomenon of ARLI became more evident after the 
introduction of PI drugs. Rates of  hepatotoxicity from registration trials of 
various PI  have ranged from 1% to 9.5%, but few patients had serious 
liver-related outcomes.
[85]
In comparison with other drugs in its class, full-
dose ritonavir has consistently been shown to be more 
hepatotoxic.
[29],[37],[41]
However, the use of low-dose ritonavir for 
pharmacokinetic boosting of other PI drugs appears to be safe.
[86]
 
Although there are a few case reports of liver-related toxicity with 
indinavir, these were in association with advanced liver disease; dose 
reduction is recommended  in patients with cirrhosis. Several cases of 
clinical  hepatitis and hepatic decompensation, including some fatalities, 
have been  associated  with  the use of tipranavir, particularly in patients 
with chronic HCV infection.
[87],[88]
 Nelfinavir, saquinavir, atazanavir, 
fosamprenavir, lopinavir and  darunavir are associated with a relatively safer 
liver toxicity profile.
[89-96] 
Amprenavir  has occasionally been associated with 
drug-related hypersensitivity reactions but only sporadically with severe 
hepatotoxicity.
[97]
 
In patients  taking  PIs, the  incidence of elevated  liver enzyme values 
is higher in those who have HIV/HCV coinfection than in those who have 
HIV alone. Recently, an FDA black-box warning was issued for the use of 
ritonavir to boost tipranavir because of increased hepatotoxicity in 
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coinfected  patients. Multivariate analysis also has shown that an increase in 
CD4 counts to more than 50 cells/mL from  baseline, which may indicate an 
underlying  immune- mediated  process, is associated with increased risk of 
elevated liver enzyme values.
[98]
 
New Antiretroviral Drug Families 
The clinical development of aplaviroc, a CCR5 antagonist, was halted 
in 2005 after the occurrence of severe hepatotoxicity.
[99]
In contrast, 
maraviroc and vicriviroc appear to have safer hepatotoxicity profiles. 
Enfuvirtide, the only approved fusion inhibitor, has demonstrated a 
consistent safety record in terms of liver toxicity.
[100]
Data on integrase 
inhibitors are still scarce, but to date MK-0518 has not been associated with 
any significant liver toxicity.
[101]
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Table 2.1 - Liver toxicity of commonly used anti- HIV medications 
Drug type Drug name Pattern of injury Comments 
Protease inhibitor Indinavir  
 
Saquinavir  
 
Nelfinavir  
 
Ritonavir  
Hepatocellular, 
distinct histologic 
pattern including 
hepatocyte ballooning, 
Kupffer cell 
activation, pericellular 
zone 3 fibrosis  
< 10% of patients 
have transaminases 
> 5 ULN Ritonavir 
inhibits P 450  
NRTI ddC d4T  
 
ddl AZT  
Microvesicular 
steatosis  
Mitochondrial 
toxicity manifesting 
as lactic acidosis  
NNRTI Nevirapine  
 
Efavirenz  
Hepatocellular  NVP associated 
with grade 4 
toxicity; FDA alert  
 
 
CAUTION 
 
 
 
 
 
 
 
 
 
 
SAFE 
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Figure 2.2 - Hepatic safety profile of antiretroviral drugs 
  
RTVV
ddl D4T 
AZT 
ABV TDF 
3TC FTC 
NVP 
EFV 
TPV 
APV DRV 
ATV LPV 
SQV NFV T20 
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Table 2.2 - Common causes and risk factors 
 
 
MECHANISMS OF LIVER TOXICITY: 
Drug-induced liver injury can be considered predictable (high 
incidence) or unpredictable (low incidence).
[102]
Liver  injury may result from 
direct toxicity of the drug or its metabolites or may be an idiosyncratic 
response in persons with a characteristic genetic predisposition. The latency 
period between the initiation of therapy and the onset of liver disease 
provides clues to its aetiology. 
Predictable hepatotoxic reactions are dose dependent and host 
independent, with the classic example being  paracetamol (acetaminophen) 
toxicity. Early-onset  toxicity (within a few days) is strong evidence for 
direct drug toxicity, particularly if there has been no previous exposure. 
Unpredictable hepatotoxic reactions are host dependent and not dose 
related.
[103]
Unfortunately, the vast majority of drug reactions are 
COMMON CAUSES AND RISK FACTORS 
Drugs 
Obesity 
Coinfection with hepatitis viruses 
Advanced disease 
Older age 
Female gender 
First exposure to antiretroviral treatment 
Significant CD4 cell gains following HAART initiation. 
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unpredictable. They occur when the drug is transformed into an  intermediate 
metabolite that is either toxic (host-mediated metabolism) or provokes an 
immunological response (hypersensitivity reaction). 
Table 2.3 - Clinical presentation of Hepatotoxicity 
  
EARLY ONSET 
 
LATE PRESENTATION 
 
Interval 1-8 weeks 2-12 months 
Mechanism Immune Mediated 
Host-mediated 
idiosyncratic 
Role of Hepatitis C 
Virus 
No Yes 
Role of CD4 counts Yes No 
Drugs( E.g) Nevirapine, Abacavir 
Stavudine, Didanosine 
 
Ritonavir 
 
Table 2.4- Mechanisms of Hepatotoxicity 
 
MECHANISMS OF HEPATOTOXICITY 
 
Direct toxicity 
Hypersensitivity reaction 
Mitochondrial toxicity 
Metabolic abnormalities 
Immune reconstitution syndrome in HBV/HCV co-infection 
 
Metabolic Host-mediated Injury: 
Host differences in drug metabolism may lead to an excess of 
potentially harmful reactive drug  metabolites when genetic polymorphisms 
affect critical metabolizing  enzymes.
[104]
The latency of onset is long (from 2 
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to 12 months), which poses problems for patient  
monitoring.
[105]
.Prototypical examples include isoniazid and troglitazone, 
these aberrant metabolic pathways may also underlie one form of drug injury 
seen in association with the nonnucleoside reverse transcriptase inhibitors 
(NNRTI) and the protease inhibitors (PI).
[106],[107]
 
Some drugs may potentiate the activation of T cell death receptors 
and/or intracellular stress pathways, leading to increased oxidative 
stress.
[108]
In response, hepatocytes  promote  mechanisms of  cytoprotection, 
such as the formation of heat shock proteins, which protect the liver against 
toxic metabolites.
[104]
 This cytoprotective response may explain the 
spontaneous normalization of liver enzymes that may occur despite 
maintenance of HAART (or other medications, such as isoniazid). 
Alternatively, the rise and fall of serum aminotransferase concentrations 
after initiation of medications may be related to a phenomenon of 
'adaptation', whereby liver function tests normalize despite ongoing drug 
exposure.
[109]
 
Hypersensitivity Reactions: 
Allergic phenomena are idiosyncratic to the host, have an intermediate 
onset of  latency (from a few days to 8 weeks) and  are  not  dose related. 
The incidence of  hypersensitivity reactions  is about 1 in 1000 in the general 
population but is more common in patients with HIV.
[110] 
Prototypical 
examples  include phenytoin and sulphonamides, which can cause rash, 
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fever, eosinophilia and hepatitis. The temporal relationship between 
symptoms and signs and the initiation of the suspected culprit drug are 
helpful in distinguishing this type of drug reaction. Clearly, rechallenges 
should be avoided if drug hypersensitivity is suspected.  
Hypersensitivity reactions have been reported with nevirapine, 
abacavir and  less frequently with amprenavir, both in HIV-infected  patients 
and in subjects receiving HIV prophylaxis after  potential exposure.
[111]
 
These immune-mediated drug reactions may involve the generation of 
neoantigens formed  by the covalent bonding of liver proteins with reactive 
drug metabolites.
[104],[112]
 
Mitochondrial Toxicity: 
Mitochondria play a major role in energy production and glucose and 
fat metabolism, but they are also the main source of reactive oxygen species, 
which can lead to cellular demise. The most infamous example of severe 
mitochondrial damage occurred with the use of the nucleoside analogue 
fialuridine for the treatment of HBV. During the initial stages of the study, 
several participants developed lactic acidosis and hepatic failure.
[113]
 Chronic 
therapy with nucleoside reverse transcriptase inhibitors (NRTI) for the 
treatment of HIV can also lead to mitochondrial toxicity after long-term 
exposure. This drug class selectively inhibits DNA polymerase-γ, which is 
responsible for replication of mitochondrial DNA. Diminished  
mitochondrial function may lead to a decrease in oxidative phosphorylation, 
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which in turn leads to aberrations in pyruvate metabolism and accumulation 
of lactate.
[114]
 
The presence of chronic HCV infection, which is quite prevalent in HIV-
infected patients may increase a patient's susceptibility to antiretroviral drug-
related mitochondrial stress and damage.
[115]
HCV core protein causes 
mitochondrial injury, leading to excessive production of reactive oxygen 
species.
[116-118]
 This leads to oxidative stress, which is enhanced in the 
presence of tumour necrosis factor, alcohol or nucleoside analogues. 
Consequently, exposure to any nucleoside analogues either for the treatment 
of HIV (e.g., didanosine) or for HCV [e.g., tribavirin (ribavirin)] may further 
enhance mitochondrial toxicity.
[119]  
Immune Reconstitution Phenomena: 
ARLI associated with HAART-induced CD4 T cell recovery has been 
attributed to immune reconstitution phenomena, particularly in the setting of 
chronic HBV and occasionally in patients with chronic HCV. 
Hepatitis B. Cell-mediated immunity plays a central role in the pathogenesis 
of chronic HBV.
[120]
 For example, in an HIV/HBV coinfected patient with 
advanced immunosuppression, HBV replication generally increases but 
HBV-related  liver inflammation lessens and  transaminase levels 
decline.
[121]
 Conversely, when HAART is initiated improved cellular 
immunity can lead to flares in liver enzymes 
[122]
 and spontaneous 
seroconversion 
[123]
 even in the absence of any anti-HBV active 
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drug.
[124]
Liver enzyme flares in HIV/HBV-coinfected patients taking 
antiretroviral therapy need to be carefully interpreted with concomitant 
evaluation of serum HBV DNA in order to assign causality correctly. Liver 
enzyme elevations in HIV/HBV-coinfected patients following initiation of 
antiretroviral therapy can be caused by (i) direct drug-related liver injury (ii) 
immune reconstitution in patients positive for HBV surface antigen 
(HBsAg), (iii) seroconversion in patients positive for HBV 'e' antigen and/or 
HBsAg, (iv) HBV reactivation in inactive carriers and occasionally in those 
with resolved HBV infection. 
Hepatitis C. However, antibody responses to HCV do not necessarily 
correlate with reconstitution of cellular immune function and initiation of 
HAART does not imply restoration of HCV-specific T cell responses.
[125]
 
Moreover, the role that cellular immunity plays in the pathogenesis of 
chronic HCV is not as clear as for HBV.
[120]
Finally, conflicting results have 
been reported on whether gains in absolute numbers of CD4 T cells correlate 
with flares of  transaminases.
[135],[136],[126],[127]
Although immune reconstitution 
remains an attractive theory and it may certainly explain clinical events in a 
subset of HIV patients with HCV 
[128],[129] 
more evidence needs to be 
gathered before any conclusions can be drawn. 
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Novel Potential Mechanisms for Antiretroviral Drug-related Injury: 
Hepatic Steatosis: 
 Insulin resistance, hyperlipidaemia and visceral adiposity are the 
metabolic and morphological abnormalities that have been intrinsically 
linked to the development of hepatic steatosis in the general population.
 [130]
 
These same metabolic and morphological aberrations coexist in a high 
percentage of HIV-infected patients and are known as the lipodystrophy 
syndrome.
[131]
 Several studies have found that hepatic steatosis is highly 
prevalent in HIV-seropositive patients, particularly in those with chronic 
HCV and/or receiving NRTI drugs with high mitochondrial toxicity 
profiles.
[132],[133]
 
Hepatic steatosis produces substrates for lipid peroxidation; this 
results in the basal formation of  potentially harmful reactive oxygen species, 
which can lead to liver injury.
[134],[136]
 Furthermore, HCV genotype 3 
infection, which induces hepatic steatosis through a virally mediated 
cytopathic effect has been associated with an increased risk of ARLI.
[137-
139]
These studies suggest that liver steatosis itself may be a predisposing 
factor for drug-related toxicity 
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 ARLI  associated with overt jaundice with increased direct bilirubin 
levels has a high mortality rate. Medications should be immediately 
discontinued. 
 If a patient complains of symptoms consistent with mitochondrial toxicity 
in association with an elevated lactate level, medications should be 
immediately discontinued. 
 If the patient has symptoms consistent with drug hypersensitivity, the 
medication  should be stopped immediately and readministration can be 
fatal. 
 Medications should be discontinued promptly if plasma ALT or AST is 
greater than 10 times the upper limit of normal (grade 4), even if the 
patient is asymptomatic.
[140],141]
For patients with advanced liver disease, 
more conservative management should be exercised to avoid hepatic 
decompensation 
Spontaneous Improvement in Transaminases Despite Drug 
Continuation: 
In assessing drug toxicity, mild elevations of  serum  transaminases 
are commonly seen and often improve despite administration of the                    
same drug.
[142]
 This has also been observed with the antiretroviral 
medications, particularly with PI use. Based upon these data, some authors 
have suggested that PI-containing HAART does not need immediate 
adjustment but simply careful monitoring.
[143]
 It should be emphasized that 
most of these patients had asymptomatic elevations of transaminases. 
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Always consider alternative causes for hepatitis including viral hepatitis, 
cholecystitis, opportunistic infections and alcohol or cocaine use. 
Table 2.5- Monitor for Liver Enzymes and Hepatotoxicity Symptoms 
Time After Initiation 
of HAART 
Monitor for Liver Enzymes 
and Hepatotoxicity Symptoms 
0–1 month Every 2 weeks 
18 weeks Monthly 
Week 19 onward Every 3 months 
 
Figure 2.4 - Algorithm for the management of patients with ART-related                 
Hepatotoxicity. 
  
Aim of the study 
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AIM OF THE STUDY 
The study was conducted with the objective of  
1. Estimation of  incidence of drug induced hepatotoxicity in patient 
receiving  HAART therapy for HIV/AIDS 
2. To analyse the risk factors that are associated with drug induced 
hepatotoxicity in these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Materials & methods 
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MATERIALS & METHODS 
About 1250 patients who receive ART were screened and patients 
with evidence of liver dysfunction were isolated. Study population was 
selected as follows.50 adult patients of both sexes infected with HIV and 
fulfil the WHO criteria for clinical AIDS receiving HAART for a period of 
more than 1 month were included in the study. 
Table 4.1 – Patient Selection 
PATIENT SELECTION 
INCLUSIVE CRITERIA 
Patients with HIV infection 
i. who receive HAART therapy for > 1 month 
 
EXCLUSION CRITERIA 
i. Patients with base line LFT abnormal 
ii. Evidence of extrahepatic cause of jaundice 
iii. Past history of jaundice 
iv. Clinical evidence of liver disease at the institution of HAART 
v. Antenatal mothers 
vi. Children < 13 years 
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PROTOCOL 
1. All patients who receive HAART therapy who met the above criteria 
were included in the study 
2. The following were noted in each patient 
i. Age 
ii. Sex 
iii. BMI 
iv.Alcohol usage 
v. Smoking 
vi. H/o jaundice in the past 
vii. Drug allergy 
viii.Diabetes 
ix. Tuberculosis (pulmonary/ extra pulmonary) 
x. Mode of acquisition of HIV 
xi. Nadir CD4 count 
xii. Latest CD4 count 
xiii. Socio economic status 
xiv. Dose of each drug 
xv. Duration of therapy of each drug 
xvi. Drug withdrawal 
xvii. Other adverse reaction with the drug 
xviii. Antitubercular therapy (ATT) 
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xix. Antifungals 
xx. Antibiotics 
3. Base line LFTs were measured 
4. Those who have abnormal LFT following were noted 
a) USG 
b) HBsAg, anti HCV antibodies 
c) Chest X ray 
d) Complete blood count 
e) Bleeding time 
 
THE STUDY 
STUDY DESIGN  :      Retrospective Analytical Study 
VENUE     : Tirunelveli Medical College & Hospital,  
Tirunelveli 
DURATION               : 12 months 
 
COLLABORATING DEPARTMENTS 
ART CLINIC, Tirunelveli Medical College &  Hospital, Tirunelveli 
LIVER CLINIC, Tirunelveli Medical College &  Hospital, Tirunelveli 
STASTICAL ANALYSIS 
Statistical analyses were made by One way ANOVA F test using SSPS 
software. 
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RISK FACTORS FOR HEPATOTOXICITY FOLLOWING HAART 
IN HIV PATIENTS 
PROFORMA 
S.NO. 
NAME                  AGE                         SEX                       UNIT 
OCCUPATION:                                              ADDRESS 
CONTACT NO.                                              HOSPITAL NO 
SYMPTOMS 
 
PRIMARY SYMPTOMS : 
GI SYMPTOMS 
Fever 
Jaundice 
Loss of appetite 
Loss of weight 
Pruritus 
GI bleed 
PAST HISTORY : 
Jaundice 
Abdominal surgery 
Blood transfusions 
Hepatotoxic drug intake 
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Alcohol /Smoking 
Tobacco usage of other means 
IV Drug Use 
Drug abuse 
Marital status 
Promiscuity M2F / M2M 
SIGNS : 
General 
Weight height 
Nutrition  
BMI 
Pallor 
Oral lesions 
Jaundice 
Evidence of liver cell failure 
Ascites 
Cutaneous bleed 
Hepatic encephalopathy 
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DURATION OF HAART: 
Table 4.2 – Duration of HAART 
DRUGS DOSE Started on Stopped on 
    
    
    
ATT 
Table 4.3 – ATT 
DRUGS DOSE DURATION 
   
   
   
 
OTHER ANTIVIRALS, ANTIFUNGAL 
Antibiotics 
Other drugs 
Pretreatment LFT      Serial LFT 
HBsAg      Anti HCV 
  
  
Results 
 
 
 Baseline data 
Total screened : 1250 
Study population   consi
dysfunction. 
Incidence of  Hepatotox
Mortality : 2 % 
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Figure 5.1 – Sex Distribution 
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Figure 5.2 – Alcohol 
Figure 5.3 – HAART Drugs 
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Figure 5.4 – Incidence of HBV 
 
Figure 5.5 – Incidence of HCV 
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Descriptive Statistics 
Table 5.1 – Descriptive Statistics 
 N Min. Max Mean S.D 
AGE 50 23 58 38.92 8.926 
BMI 50 14.2 25.7 18.982 2.5976 
CD4COUNT 50 41 184 105.42 31.031 
TB 50 3 7 4.40 0.910 
SGOT 50 250 397 332.10 45.651 
SGPT 50 235 499 395.44 64.074 
ALP 50 184 285 235.18 29.230 
DURATION OF 
HAART 
50 2.92 7.54 4.4030 1.0977 
 
AGE GROUP : 
Table 5.2 – Age Group Analysis with LFT 
 < 40 yrs >40 yrs Oneway ANOVA F   
Test  Mean SD Mean SD 
TB 4.02 0.551      4.92 1.056       F =4.179,p =0.000 
SGOT 314.10   44.481    356.95   34.896    F =2.050,p =0.040 
SGPT 376.03  51.211    422.24   71.321   F =1.302,  p =0.258 
ALP 219.52  19.057    256.81   27.164    F =1.817,  p =0.072 
 
Considering Age as an independent factor for elevated liver enzymes, 
2 age groups were analysed ( A < 40 yrs, B >40). Though age >40 yrs 
showed elevated liver enzymes,There was no statistical significance 
difference between age and hepatotoxicity. 
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SEX : 
Table 5.3 –   Analysis of sex with LFT 
 Male Female Oneway ANOVA F 
test  Mean SD Mean SD 
TB 4.52 1.100 4.20 0.414 F=1.495  p=0.227 
SGOT 319.81 53.296 352.16 15.942 F=6.591  p=0.013 
SGPT 393.94 78.328 397.89 30.663 F=0.044  p=0.835 
ALP 244.32 31.899 220.26 15.846 F=9.339  p=0.004 
 
Comparing the means of liver function tests with Sex  ,sex show no 
statistically significant difference with hepatotoxicity.( p >0.05) 
BODY MASS INDEX (BMI) 
Analysis of data with BMI as an independent variable show no 
statistically significant difference between BMI and hepatotoxicity. (p>0.05). 
Table 5.4– Analysis of  BMI with LFT 
 BMI  
 <18.5 > 18.5  
 
Mean SD Mean SD 
Oneway ANOVA F 
Test 
TB 4.23 0.937 4.55 0.875 F=1.566,  p=0.217 
SGOT 325.71 54.357 338.00 35.930 F=0.903,  p=0.347 
SGPT 390.33 68.908 400.15 60.250 F=0.289,  p=0.593 
ALP 230.92 33.060 239.12 25.210 F=0.981,  p=0.327 
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Alcohol: 
Table 5.5 – Analysis of Alcohol with LFT 
 ALCOHOL 
 YES NO  
 Mean SD Mean SD One wayANOVA F Test 
TB 4.61 1.216 4.27  0.650 F=1.577 p=0.215 
SGOT 335.53 51.418 330.00 42.492 F=0.170 p=0.682 
SGPT 426.68 69.585 376.29 52.945 F=8.385 p=0.006 
ALP 247.00 30.944 227.94 26.043 F=0.006 p=0.024 
 
Analysing with alcohol and hepatotoxicity did not show any statistical 
significance difference between them. (p> 0.05). 
CD4 COUNT: 
Table 5.6 –Analyses of CD4 counts with LFT. 
 < 105 >105  
 
Mean SD Mean SD 
Oneway ANOVA F 
test 
TB 4.65 0.878 4.13 0.880 F=4.517 p=0.039 
SGOT  359.77  20.294  302.13  46.788 F=32.821  p=0.000 
SGPT  421.92  55.619  366.75  61.092 F=11.175p= 0.002 
ALP  242.65  31.079  227.08 25.274  F=3.889 p=0.049 
 
The association of hepatotoxicity with different CD4 counts catagories 
was analyzed.  Analyses show statistically significant difference between   
the patients belonging to CD4 count < 105and hepatotoxicity.(p< 0.05). 
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HBV: 
Table 5.7- Analysis of Co-infection with HBV with LFT 
 HBV 
Oneway ANOVA 
F test 
YES NO 
Mean SD Mean SD 
TB 4.98 1.133 4.25 0.910 F=5.549 p=0.023 
SGOT 372.40 22.192 322.02 45.651 F=11.910  p=0.001 
SGPT 463.70 36.185 378.38 64.074 F=19.561p=0.000 
ALP 259.10 28.041 229.20 29.230 F=9.890p=0.003 
 
Coinfection with HBV increases the risk of hepatotoxicity. The data 
analysed show statistically significant difference between with HBV 
positivity& hepatotoxicity. (p< 0.05) 
HCV: 
Table 5.8 - Analysis of Co-infection with HCV with LFT 
 HCV Oneway ANOVA F 
test 
YES NO 
Mean SD Mean SD 
TB 6.13 0.252 4.29 0.819 F=14.851p=0.000 
SGOT 386.00 12.767 328.66 44.847 F=4.794p=0.033 
SGPT 487.67 8.386 389.55 61.482 F=5.422p=0.024 
ALP 271.67 5.508 232.85 28.573 F=5.422p=0.024 
 
Coinfection with HCV increases the risk of hepatotoxicity. The data 
analysed show statistically significant difference between HCV positivity 
and hepatotoxicity.(p<0.05). 
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COMBINATION OF ALCOHOL,HBV& HCV: 
Table 5.9 - Analysis with combination of HBV, HCV & Alcohol with LFT. 
 ALCOHOL-HBV-HCV 
Oneway ANOVA F 
Test 
YES NO 
Mean SD Mean SD 
TB 5.31 1.075 4.20 0.745 F=13.897p=0.001 
SGOT 376.56 24.414 322.34 43.491 F=12.946p=0.001 
SGPT 480.78 16.791 376.71 54.539 F=31.646p=0.000 
ALP 271.56 9.235 227.20 25.817 F=25.495p=0.000 
[ 
On combining HBV, HCVcoinfection and alcohol abuse there was a  
statistically significant difference between hepatotoxicity and HBV,HCV 
and alcohol abuse. (p< 0.05). 
REGIMEN 
Table 5.10 - Analysis between various Treatment Regimens(ZLN & ZLE 
Regimen) with LFT 
 REGIMEN Oneway 
Anova   
F Test 
ZLN ZLE SLN SLE 
Mean SD Mean SD Mean SD Mean SD 
TB 4.41 1.035 3.98 0.340 4.34 0.894 4.64 0.916 
F=0.549 
p=0.651 
SGOT 322.69 48.981 291.00 61.281 337.53 40.315 351.36 35.767 
F=2.201 
p=0.101 
SGPT 386.13 65.207 389.00 115.761 404.11 51.097 396.36 68.701 
F=0.231 
p=0.874 
ALP 231.13 26.066 229.75 32.725 233.63 31.261 245.73 30.365 
F=0.629 
p=0.600 
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Considering associations between various treatment regimens 
REGIMEN 1 :Zidovudine + Lamivudine + Nevirapine  (ZLN) 
REGIMEN 2:Zidovudine + Lamivudine + Efavirenz    (ZLE) 
REGIMEN 3 :Stavudine + Lamivudine + Nevirapine  (SLN) 
REGIMEN 4: Stavudine + Lamivudine + Efavirenz  (SLE) and Liver 
Function Test (TB,AST,ALT,ALP,). 
The data were analysed by One way ANOVA F test. There was no statistical 
difference between different regimens in causing hepatotoxiciy. (p> 0.05). 
Table 5.11- Analysis of Duration of HAART and LFT 
 DURATION OF HAART Oneway Anova   
F Test  Mean SD Mean SD 
TB 4.82 0.944 4.18 0.826 F=5.976 p=0.018 
SGOT 357.41 31.853 319.06 46.563 F=9.252 p=0.004 
SGPT 409.18 64.189 388.36 63.831 F=1.188 p=0.281 
ALP 242.82 31.235 231.24 27.811 F=1.790 p=0.187 
 
Comparing with duration of HAART  and hepatotoxicity ,it  did not 
show any statistical significance. (p >0.05).  
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Table 5.12 – Analysis of Patients receiving HAART and ATT drugs with LFT 
 
ATT 
Oneway ANOVA F test YES NO 
Mean SD Mean SD 
TB 4.46 0.846 4.37 0.947 F=0.091 p=0.764 
SGOT 335.27 49.819 330.74 44.443 F=0.101 p=0.752 
SGPT 394.40 79.084 395.89 57.799 F=0.006 p=0.941 
ALP 241.47 30.685 232.49 28.613 F=0.991 p=0.324 
 
Comparing patients receiving HAART and ATT drugs with 
hepatotoxicity, show no significant difference.(p>0.05). 
  
  
Discussion 
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DISCUSSION 
 
There is an increase in the reporting of drug induced liver injury  
following ART therapy since 1995 following wide spread usage of 
antiretrovirals 
[144]  . 
The incidence of drug hepatotoxicity has been variously reported. It 
ranged from 5% to 30% in different series (17 cohorts and 2 metaanalyses). 
Less often they cause steatosis, Lactic acidosis and encephalopathy with 
mortality rates between 0.1 to 7%.Our incidence is likely to be around 4% 
when grade 3 or 4 injury is taken as cut off limit. 
We compared our results with that of the literature available on this 
issue. Much of the data came from large trials like Amsterdam, CHORUS, 
ICONA and TARGET which involved more than 5100 patients.
[145-149] 
AGE, SEX AND BMI : 
Age was not considered to be an individual risk factor in most of the 
published series. Age has not been found consistently to be an independent 
risk for elevated liver enzyme values 
[145],[150],[151],[152].
 .As Large trials like 
Saves
[148]
 failed to demonstrate any correlation with age. Our series also 
found no correlation to the incidence of hepatotoxicity with age. 
Female sex was associated with increased incidence of hepatotoxicity 
in two of the major trials. Martin-Carbonero
[19]
et al and Wit et al
[147]
 have 
shown independently that female sex is an independent risk factor and the 
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risk increases with females who are obese and who drink alcohol. Our data 
found no correlation of hepatotoxicity with gender. Both sexes had equal 
incidence of liver injury. Obese patients had a higher risk of hepatic steatosis 
and liver injury (Carr A et al).  
Other studies (Sampras K et al) have shown that malnutrition and low 
BMI are also contributory factors in hepatic injury in Asian and African 
populations (Sampras K et al). In our series there is a no correlation with 
liver injury (Bilirubin level, AST, ALT ) with BMI .Most of  our patients in 
the sample  had their BMI within normal limit. Since our study population 
were small in number, this parameter has to be reevaluated on larger 
population. 
DRUGS AND REGIMENS: 
Previously number of reports of increased liver injury were attributed 
to certain drugs like Zidovudine, Nevirapine , full dose Ritonavir. Review of 
17 clinical trials between 1991 to 2001 in FDA database attributes risk of 
liver injury for Nevirapine (NVP) and Efavirenz (EFZ). 
In 2NN study, post exposure prophylaxis of NVP was associated with 
severe liver injury and it was recommended to exclude NVP from PEP 
programs. Our series included 4 standard regimen (Zidovudine  + 
Lamivudine + Nevirapine , Zidovudine + Lamivudine + + Efavirenz, 
,Stavudine + Lamivudine + Nevirapine, Stavudine + Lamivudine + 
Efavirenz,). When these were compared with the incidence of liver injury 
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CD4 COUNT: 
The correlation with CD4 count and hepatotoxicity was found in our 
study. Patients with CD4 < 105 cells ran a higher risk of hepatotoxicity and 
death. This is attributed to profound state of immune suppression and loss of 
liver regeneration functions. Studies by Saves had similar results. A study by 
Sulkowski
[154] 
showed that a rise in CD4 count following HAART 
predisposes to severe hepatic injury. He attributes this phenomenon to 
immune reconstitution syndrome where restoration of cell mediated 
immunity caused aggressive hypersensitivity reaction to drugs. This 
phenomenon was also confirmed by other recentstudies.
[157],[147],[155]
  
Most of our patients had CD4 counts moderately elevated after 
induction of ART and this phenomenon was not observed in our series.  
 
 
 
 
 
 
 
 
 
 
  
Conclusion 
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CONCLUSIONS 
 
The following were concluded at the end of the study 
1. Drug induced liver injury occurs in 4% of patients following HAART  
therapy. 
2. The risk factors for hepatotoxicity identified were  Low CD4 count,  
HBV co-infection, HCV infection and combined HBV,HCV co-infection 
& alcohol usage. 
3. Age, Sex,BMI,did not have any correlation with the incidence and  
severity of hepatotoxicity. 
4. Similarly alcohol usage alone, various regimens, Duration of  
HAART did not have any correlation with the incidence and severity of 
hepatotoxicity. 
5. Mortality rate was  2%.(Patient died of acute fulminant hepatic  
Failure). 
 
 
 
 
 
 
 
  
Summary 
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SUMMARY 
 
The study was initiated with the primary aim of finding out the 
clinical profile and risk factors for the hepatotoxicity in patients receiving 
HAART therapy for AIDS. 
A total of 1250 patients were screened and patients who developed 
liver injury (grade 3 or 4) during ART therapy were selected. About 50 adult 
patients of both the sexes were included in the study. Records of these 
patients were analysed. Further testing was done as needed. 
Various parameters were noted. Statistical analysis was done by 
Oneway ANOVA F test,  in which correlation between various parameters 
and hepatotoxicity were analysed. Results were tabulated and compared with 
various published series worldwide. 
According to our series, the major risk factors for hepatotoxicity were 
Hepatitis B coinfection(20%),Hepatitis C coInfection(6%), Low CD4 counts,  
alcohol abuse in HBV ,HCV positive patients. 
The risk of liver injury was independent of age, sex, BMI, various 
drug combinations, Duration of HAART. These results were comparable 
with publishes series from various countries although subtle differences 
exist. 
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